Stockscreener 앱 받기
27.78
0.47%
0.13
시간 외 거래:
27.98
0.20
+0.72%
전일 마감가:
$27.65
열려 있는:
$27.77
하루 거래량:
564.74K
Relative Volume:
0.92
시가총액:
$1.57B
수익:
$384.10M
순이익/손실:
$-9.07M
주가수익비율:
-198.43
EPS:
-0.14
순현금흐름:
$11.10M
1주 성능:
+29.39%
1개월 성능:
+36.44%
6개월 성능:
+26.10%
1년 성능:
+38.35%
1일 변동 폭
$27.56
$28.56
1주일 범위
$22.23
$28.56
52주 변동 폭
$17.38
$28.56
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
명칭
Kiniksa Pharmaceuticals International Plc
전화
(781) 431-9100
주소
23 OLD BOND STREET, FLOOR 3, LONDON
KNSA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
27.78 | 1.57B | 384.10M | -9.07M | 11.10M | -0.14 |
|
ZTS
Zoetis Inc
|
158.06 | 68.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.38 | 47.71B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.63 | 46.12B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.39 | 18.55B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
298.70 | 13.40B | 2.76B | 1.11B | 898.10M | 22.77 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2024-09-13 | 개시 | Jefferies | Buy |
| 2024-05-03 | 개시 | Wells Fargo | Overweight |
| 2020-06-29 | 재확인 | BofA Securities | Buy |
| 2020-04-01 | 개시 | BofA/Merrill | Buy |
| 2019-03-11 | 개시 | Barclays | Overweight |
| 2018-12-12 | 재확인 | Wedbush | Outperform |
| 2018-06-19 | 개시 | JMP Securities | Mkt Outperform |
모두보기
Kiniksa Pharmaceuticals International Plc 주식(KNSA)의 최신 뉴스
Insider’s View: Deciphering Kiniksa Pharmaceuticals International Plc (KNSA)’s Financial Health Through Ratios - DWinneX
How should investors view Kiniksa Pharmaceuticals International Plc (KNSA)? - uspostnews.com
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $2,265,339, According to a Recent SEC Filing - marketscreener.com
Kiniksa Pharmaceuticals Executives Sell Shares - TradingView
Wall Street analysts’ outlook for Kiniksa Pharmaceuticals International Plc (KNSA) - Sete News
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2025 Earnings Call Transcript - Insider Monkey
3 Stocks Including Kiniksa Pharmaceuticals International That May Be Priced Below Intrinsic Value Estimates - Yahoo Finance
Kiniksa Pharmaceuticals International PLC (KNSA) Q1 2025: Everyt - GuruFocus
Examining the Potential Price Growth of Kiniksa Pharmaceuticals International Plc (KNSA) - knoxdaily.com
Kiniksa (KNSA) Partners with Carly Pearce for Health Awareness C - GuruFocus
Kiniksa Pharmaceuticals International Plc (KNSA) Stock: A Year of Decreases and Increases - investchronicle.com
Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis - GlobeNewswire
Country Star Carly Pearce Opens Up About 4-Year Struggle With Rare Heart Disease in New Campaign - Stock Titan
An Intrinsic Calculation For Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Suggests It's 41% Undervalued - Yahoo Finance
Kiniksa raises ARCALYST 2025 revenue guidance to $605M amid strong Q1 performance - MSN
Decoding Kiniksa Pharmaceuticals International PLC (KNSA): A Str - GuruFocus
Wedbush Raises Price Target on Kiniksa Pharmaceuticals to $36 From $34, Maintains Outperform Rating - marketscreener.com
Kiniksa Pharmaceuticals: A Biotech Stock on the Rise, But What’s Next? - RagingBull
Kiniksa Pharmaceuticals International, plc Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Kiniksa Pharmaceuticals Surpasses Q1 2025 Revenue Estimates with $137.8 Million, EPS Details Unavailable - GuruFocus
Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Res - GuruFocus
Kiniksa Pharmaceuticals Swings to Q1 Net Income, Revenue Increases - marketscreener.com
KNSA: Kiniksa Forecasts Increased ARCALYST Revenue for 2025 | KN - GuruFocus
Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results - TradingView
Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution - GlobeNewswire
Kiniksa Q1 Earnings: ARCALYST Revenue Soars 75% to $138M, 2025 Guidance Boosted to $605M - Stock Titan
Examining the Future: Kiniksa Pharmaceuticals's Earnings Outlook - Benzinga
Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025 - GlobeNewswire
Kiniksa Pharmaceuticals Sets Q1 2025 Earnings Call Date: How to Access Live Results and Portfolio Updates - Stock Titan
Its Stock Has Paid Off Big Time For Kiniksa Pharmaceuticals International Plc - Sete News
Kiniksa Pharmaceuticals introduces new incentive plan By Investing.com - Investing.com India
Kiniksa Pharmaceuticals introduces new incentive plan - Investing.com Australia
Kiniksa Pharmaceuticals chief commercial officer sells $370,475 in stock By Investing.com - Investing.com South Africa
Kiniksa Pharmaceuticals chief commercial officer sells $370,475 in stock - Investing.com Australia
Lacklustre Performance Is Driving Kiniksa Pharmaceuticals International, plc's (NASDAQ:KNSA) Low P/S - simplywall.st
SEC Form DEFA14A filed by Kiniksa Pharmaceuticals International plc - Quantisnow
Analysts Set Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) PT at $37.17 - Defense World
KNSA Stock Sees Decline of Approximately -1.89% in Last Five Days - knoxdaily.com
Kiniksa CFO Mark Ragosa sells shares worth $368,465 By Investing.com - Investing.com South Africa
Kiniksa CFO Mark Ragosa sells shares worth $368,465 - Investing.com India
Kiniksa Pharmaceuticals International PLC (KNSA) Shares Down 1.8 - GuruFocus
Kiniksa pharmaceuticals CFO Mark Ragosa sells $469,923 in stock By Investing.com - Investing.com South Africa
Kiniksa pharmaceuticals CFO Mark Ragosa sells $469,923 in stock - Investing.com
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Earns Buy Rating from Analysts at Citigroup - MarketBeat
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CAO Michael R. Megna Sells 9,051 Shares - MarketBeat
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives $36.60 Average Target Price from Analysts - MarketBeat
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Sells $809,277.00 in Stock - MarketBeat
Globeflex Capital L P Boosts Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Sells 17,118 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) - MarketBeat
Kiniksa Pharmaceuticals CFO Mark Ragosa sells $809k in shares By Investing.com - Investing.com Canada
Kiniksa Pharmaceuticals CAO Michael Megna sells shares worth $203,194 By Investing.com - Investing.com Australia
Kiniksa Pharmaceuticals International Plc (KNSA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.03%
0.06%
자본화:
|
볼륨(24시간):